CINECA IRIS Institutional Research Information System

GIACCONE, Luisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.685
EU - Europa 6.429
AS - Asia 4.033
SA - Sud America 306
OC - Oceania 105
AF - Africa 88
Continente sconosciuto - Info sul continente non disponibili 33
Totale 19.679
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.461
CN - Cina 1.761
IT - Italia 1.564
DE - Germania 1.119
SG - Singapore 617
IE - Irlanda 608
SE - Svezia 576
FR - Francia 531
KR - Corea 519
JP - Giappone 363
FI - Finlandia 326
GB - Regno Unito 277
AT - Austria 274
ES - Italia 236
UA - Ucraina 217
PL - Polonia 180
CA - Canada 169
VN - Vietnam 145
BR - Brasile 141
IN - India 126
TR - Turchia 121
NL - Olanda 89
AU - Australia 84
ID - Indonesia 76
TW - Taiwan 76
AR - Argentina 73
RU - Federazione Russa 59
BE - Belgio 58
CH - Svizzera 48
CO - Colombia 47
MX - Messico 45
HK - Hong Kong 43
BY - Bielorussia 41
GR - Grecia 41
SN - Senegal 40
IR - Iran 38
TH - Thailandia 34
PT - Portogallo 33
IL - Israele 32
HU - Ungheria 29
PE - Perù 25
DK - Danimarca 23
EU - Europa 21
NZ - Nuova Zelanda 21
CZ - Repubblica Ceca 19
RS - Serbia 19
CL - Cile 17
RO - Romania 16
UZ - Uzbekistan 16
SA - Arabia Saudita 14
JO - Giordania 11
EG - Egitto 10
SI - Slovenia 10
AP - ???statistics.table.value.countryCode.AP??? 9
ZA - Sudafrica 9
HR - Croazia 8
NG - Nigeria 8
TN - Tunisia 8
AE - Emirati Arabi Uniti 7
MA - Marocco 7
NO - Norvegia 7
AZ - Azerbaigian 6
LT - Lituania 5
MY - Malesia 5
PK - Pakistan 5
BG - Bulgaria 4
KE - Kenya 4
QA - Qatar 4
BA - Bosnia-Erzegovina 3
CU - Cuba 3
CY - Cipro 3
EE - Estonia 3
PA - Panama 3
PH - Filippine 3
SY - Repubblica araba siriana 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
CR - Costa Rica 2
EC - Ecuador 2
MD - Moldavia 2
BD - Bangladesh 1
BN - Brunei Darussalam 1
BO - Bolivia 1
GT - Guatemala 1
IQ - Iraq 1
JM - Giamaica 1
KW - Kuwait 1
LU - Lussemburgo 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
TG - Togo 1
TZ - Tanzania 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 19.679
Salva come PNG Salva come JPEG
Città #
Beijing 887
Chandler 830
Dublin 598
Santa Clara 530
Singapore 487
Fairfield 460
Ashburn 365
Houston 337
Ann Arbor 299
Wilmington 290
Torino 283
Vienna 241
Villeurbanne 241
Woodbridge 235
Seattle 226
Nyköping 223
Redwood City 222
Medford 208
Princeton 194
Cambridge 182
Jacksonville 176
Columbus 166
Pisa 163
Dearborn 158
Warsaw 144
Milan 134
Munich 130
Dong Ket 109
Turin 108
Tokyo 106
Shanghai 98
New York 86
San Mateo 84
Guangzhou 77
Helsinki 75
Jakarta 72
Florence 71
Madrid 61
Nanjing 54
Taipei 52
Toronto 52
Rome 50
Hangzhou 48
Paris 48
Düsseldorf 47
Fremont 47
Boardman 43
Boston 43
Seoul 39
San Diego 38
Brussels 35
Wuhan 34
Buenos Aires 33
Hefei 33
Zhengzhou 32
Ankara 31
London 31
Los Angeles 30
Duncan 29
Nürnberg 29
Bologna 28
Rochester 26
São Paulo 26
Chennai 25
Chicago 25
Istanbul 25
Phoenix 25
Xian 25
Chengdu 22
Osaka 22
Frankfurt am Main 21
Ottawa 21
Barcelona 20
Norwalk 20
Bogotá 19
Lima 19
Melbourne 19
Montreal 19
Faenza 18
Tianjin 18
Valencia 18
Belgrade 17
Budapest 17
Essen 17
Philadelphia 17
Salt Lake City 17
Changsha 16
Nanning 16
Washington 16
Amsterdam 15
Falkenstein 14
Jinan 14
Moscow 14
Mountain View 14
Sydney 14
Athens 13
Des Moines 13
Falls Church 13
Fuzhou 13
Hebei 13
Totale 10.978
Salva come PNG Salva come JPEG
Nome #
Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation 2.757
Use of sodium hyaluronate and synthetic amino acid precursors of collagen for the symptomatic treatment of mucositis in patients undergoing haematopoietic stem cell transplants 997
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. 494
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors 482
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation 404
Extracellular vesicles as potential biomarkers of acute graft-vs.-host-disease 300
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives 292
An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation 270
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 267
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma 265
The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors 258
EXTRACELLULAR VESICLES AS POTENTIAL BIOMARKER FOR ACUTE GVHD 243
CLINICAL IMPACT OF IMMUNOPHENOTYPIC REMISSION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MULTIPLE MYELOMA 239
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives 239
'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO) 230
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study 214
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 205
Ruxolitinib in steroid refractory graft-vs.-host disease: A case report 194
Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia 185
Risk of hepatitis B and efficacy of treatment with lamivudine in patients undergoing allogeneic stem cell transplant 181
Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation. 166
Effect of in vivo T-cell depletion with ATG on cytomegalovirus (CMV) induced antileukemic effect in patients with acute myeloid leukemia (AML) receiving grafts from unrelated donors. 165
Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma. 151
null 148
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the italian bone marrow donor registry. 147
Late-Onset Hepatic Veno-Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide 145
THYMIC FUNCTION AND EARLY T CELL RECONSTITUTION AFTER HAPLOIDENTICAL MARROW TRANSPLANTATION 143
Restoring natural killer cell immunity against multiple myeloma in the era of new drugs 143
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma 143
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 141
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. 141
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice 139
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 134
Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry 132
Trichoderma species fungemia after high-dose chemotherapy and autologous stem cell transplantation: a case report 130
AISF position paper on HCV in immunocompromised patients 126
Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients 124
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 123
Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma 122
ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ADULTS WITH MYELODYSPLASTIC SYNDROMES (MDS): RELEVANCE OF PRE-TRANSPLANT DISEASE STATUS. 121
IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA 120
IMMUNE RECONSTITUTION OF THE T CELL COMPARTMENT IN MULTIPLE MYELOMA PATIENTS FOLLOWING ALLOGENEIC NON MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION 120
A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo. 117
A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL 117
IMMUNOPHENOTYPIC REMISSION AFTER ALLOGRAFTING IN MULTIPLE MYELOMA 116
Thymic Function Following Nonmyeloablative Allografting for the Treatment of Hematological Malignancies 114
Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant. 113
Role of allogeneic stem cell transplantation in multiple myeloma 112
Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma 111
Topical tacrolimus and periodontal therapy in the management of a case of oral chronic GVHD characterized by specific gingival localization. 110
Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients 110
Role of allogeneictransplantation in multiple myeloma in the era of new drugs. 109
Is there a role for allografting in myeloma ?: an update of a comparative study 109
IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA 108
IMMUNE RECONSTITUTION OF THE T CELL COMPARTMENT IN HEMATOLOGICAL MALIGNANCIES FOLLOWING ALLOGENEIC NON MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION 108
TREATMENT OF POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) HAEMORRHAGIC CYSTITIS WITH INTRAVESCICAL HYALURONIC ACID 107
ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA 106
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation 106
HLA-haploidentical allografting with high-dose post-transplant cyclophosphamide: clinical outcomes and immunereconstitution. 103
ASSESSMENT OF THYMIC OUTPUT IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES FOLLOWING NON-MYELOABLATIVE ALLOGRAFTING 103
Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment 100
THYMIC OUTPUT AND T CELL RECONSTITUTION FOLLOWING NON-MYELOABLATIVE ALLOGRAFTING 99
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 98
MOLECULAR REMISSION IN A MULTIPLE MYELOMA PATIENT AFTER A NON MYELOABLATIVE ALLOGENEIC TRANSPLANT: PROOF OF PRINCIPLE 96
RECONSTITUTION OF THE T CELL COMPARTMENT AND THE THYMIC FUNCTION AFTER REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION 96
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo 95
ROLE OF ALLOGRAFTING IN ACUTE LYMPHOBLASTIC LEUKEMIA: A 12 YEAR EXPERIENCE 95
Extracellular Vesicles After Allogeneic Hematopoietic Cell Transplantation: Emerging Role in Post-Transplant Complications 94
Qualitative and Quantitative Molecular Follow up of Minimal Residual Disease after Non Myeloablative Allografting for Multiple Myeloma. 94
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy 94
Exhaled nitric oxide (eNO) and pulmonary function after total body irradiation (TBI) based non myeloablative conditioning regimens and allogenic hematopoietic cell transplant 93
ROLE OF ALLOGRAFTING IN ACUTE LYMPHOBLASTIC LEUKEMIA: A 12 YEAR EXPERIENCE 90
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation 90
REAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS 88
Oral melphalan at diagnosis hampers adeguate collection of peripheral blood progenitor cells in multiple myeloma. 88
Comparison of post-transplant events and outcomes in patients affected by haematological or solid malignancies undergone to a non-myeloablative allogeneic haematopoietic stem cell transplantation in progressive disease 88
Allografting from unrelated donors in multiple myeloma: a study by the Italian bone marrow donor registry 85
Autografting followed by low dose TBI based non myeloablative allografting in newly diagnosed multiple myeloma: The Italian experience. 85
Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation 85
Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting 84
ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA 83
Double Autologous Transplant Versus Tandem Autologus - Non Myeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma. 77
Allografting in relapsed/refractory Hodgkin's lymphoma, a single-centre experience 77
AUTOGRAFTING FOLLOWED BY LOW DOSE TBI BASED NON MYELOABLATIVE ALLOGRAFTING IN NEWLY DIAGNOSED MULTIPLE MYELOMA: THE ITALIAN EXPERIENCE 77
An Update of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma. 77
LONG TERM FOLLOW UP OF A COMPARISON OF NONMYELOABLATIVE ALLOGRAFTING WITH AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA 76
IMMUNE RECONSTITUTION OF THE T CELL COMPARTMENT BY FLOW CYTOMETRY FOLLOWING ALLOGENEIC NON MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES 75
Exhaled Nitric Oxide (eNO) and Pulmonary Function after Total Body Irradiation (TBI) Based Non Myeloablative Conditioning Regimens and Allogeneic Hematopoietic Cell Transplant. 74
Impact of Allogeneic Stem Cell Transplantation on Testicular and Sexual Function 74
Disease and Comorbidity Status Predict Outcome after Nonmyeloablative Allografting for Advanced Haematological Malignancies. 73
Biomarkers for acute and chronic graft versus host disease: state of the art 73
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus Acute Lymphoblastic Leukemia study 71
REDUCED INTENSITY/NON-MYELOABLATIVE ALLOGRAFTING FOR HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA 70
IMMUNE RECONSTITUTION OF THE T CELL COMPARTMENT IN MULTIPLE MYELOMA PATIENTS FOLLOWING ALLOGENEIC NON MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION 69
CMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins 69
Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia 67
SERUM FREE LIGHT CHAINS (SFLC) ASSAY: A SUGGESTIVE NEW CRITERIA FOR EVALUATING DISEASE RESPONSE, PROGRESSION AND RELAPSE IN PLASMA-CELL DISORDERS (PD) AND A PROGNOSTIC FACTOR IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) 66
TANDEM AUTOGRAFTING-NONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: THE GITMO EXPERIENCE 66
Bortezomib and lenalidomide for multiple myeloma patients relapsed after allogeneic stem cell transplantation 65
REAL TIME QUANTITATIVE PCR SHOWS THAT PERIPHERAK BLOOD STEM CELL (PBPC) HARVESTS ARE SIGNIFICANTILY LESS CONTAMINATED THAN BONE MARROW (BM) IN MULTIPLE MYELOMA PATIENTS (MM). 65
Totale 17.000
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.652
article - articoli 0
book - libri 0
conference - conferenze 19.276
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.928
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.101 0 0 0 0 0 0 248 183 207 177 157 129
2020/20212.500 208 117 160 141 201 146 226 221 239 184 341 316
2021/20222.474 145 107 122 264 130 88 249 149 108 207 457 448
2022/20233.090 293 297 110 274 236 736 240 181 284 133 149 157
2023/20241.740 193 326 97 123 142 206 81 94 26 92 141 219
2024/20252.106 100 281 259 350 827 277 12 0 0 0 0 0
Totale 20.282